Sysmex (OTCMKTS:SSMXY) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Posted by Wayne Rhoads on May 15th, 2026

Sysmex (OTCMKTS:SSMXY – Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02), Zacks reports. Sysmex had a return on equity of 9.27% and a net margin of 8.86%.The business had revenue of $877.92 million during the quarter, compared to the consensus estimate of $862.45 million. Sysmex updated its FY 2026 guidance to 0.370-0.370 EPS.

Sysmex Price Performance

OTCMKTS SSMXY traded up $0.26 during trading hours on Friday, reaching $8.38. The company’s stock had a trading volume of 20,613 shares, compared to its average volume of 265,489. The firm’s 50-day moving average price is $8.73 and its 200-day moving average price is $9.39. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12. Sysmex has a 1 year low of $8.12 and a 1 year high of $18.10. The company has a market capitalization of $5.28 billion, a price-to-earnings ratio of 17.46 and a beta of 1.10.

Analyst Ratings Changes

Separately, Citigroup downgraded Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Get Our Latest Analysis on Sysmex

Sysmex Company Profile

(Get Free Report)

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.